Cingulate Inc.
CTx-1301
Attention Deficit/Hyperactivity Disorder (ADHD)
Resolved
35days ago
FDA decision · Jun 2, 2026
What's at stake
An FDA complete response letter on CTx-1301 for Attention Deficit/Hyperactivity Disorder (ADHD) is in focus around Jun 2, 2026.
Primary source
· SEC 8-K
verified 15h ago
“On June 2, 2026, the Company announced that the FDA has issued a CRL for its New Drug Application for CTx-1301. The FDA identified specific Chemistry, Manufacturing and Controls information requests in the CRL and did not raise any current ”